Invitation to the presentation of SenzaGen’s January-March 2025 interim report

SenzaGen's 2025 Q1 report will be published on May 14, 2025, at 08:00 AM, followed by a live webcast presentation at 12:30 on the same day. The presentation will be given by SenzaGen's President and CEO, Peter Nählstedt, with a subsequent Q&A session moderated by Rodney Alfvén, partner at Hallvarsson & Halvarsson.

The presentation will be held in Swedish.

Time: Wednesday, May 14, 12:30

Webcast
If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions:
https://senzagen.events.inderes.com/q1-report-2025

Teleconference
If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference:
https://events.inderes.com/senzagen/q1-report-2025/dial-in

The presentation can also be viewed later on SenzaGen's website: https://senzagen.com/investors/presentations/

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44

About us

SenzaGen is a corporate group that aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser. 

Attachments

Invitation to the presentation of SenzaGen's January-March 2025 interim report